A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence

Chronic Obstructive Pulmonary Disease Clinical Trial

— ADVICE  

Official title:

A 24-week Randomized, Controlled, Multicenter, Open-label Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence of COPD Subjects Receiving Ultibro® Breezhaler® Treatment Using the Concept2 Inhaler for Dose Administration and Tracking

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03379233
• Other study ID #: CIDD001D2402
• Status: Terminated
• Phase: Phase 3
• Start date: July 11, 2018
• Est. completion date: January 22, 2019

Study information

• Verified date: January 2020
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was evaluating the effect of reminder notifications and motivational/adaptive messages on treatment adherence behavior in subjects with COPD. The effect will be measured over 24 weeks on the subject's on time treatment adherence and total treatment adherence. The delivery of the medication and tracking of inhaler use is done by the Concept2 inhaler. The reminder notification, feedback on inhaler use and motivational messages are provided by the patient application, who is receiving the inhaler use information from the Concept2 inhaler.

Description:

This study was evaluating whether subjects with COPD on Ultibro® Breezhaler® clinical trial formulation once daily dosing regimen using the Concept2 inhaler in conjunction with a patient application collecting data and sending reminder notifications and motivational/adaptive messages aimed at encouraging treatment adherence, have improved treatment adherence compared to subjects using the Concept2 inhaler alone (usual care). The delivery of the medication and tracking of inhaler use is done by the Concept2 inhaler. The reminder notifications, feedback on inhaler use and motivational messages for the subject are sent by the patient application based on the received subjects inhaler use information from the Concept2 inhaler.

The effect will be measured over 24 weeks on the subject's on time treatment adherence (days when the subjects inhaled within +/- 2 hours of the subjects preferred inhalation time) and total treatment adherence (days when patient inhaled at least one dose).

The study population consisted male and female adult patients, 18 years or older with a clinical diagnosis of COPD, a smoking history of 10 pack years, receiving Ultibro Breezhaler treatment for at least 3 months prior to screening and documented poor treatment adherence.

After 6 weeks of screening patients will be randomized to either the Usual Care group in which they will continue to receive Ultibro Breezhaler treatment via the Concept2, or the Telehealth group in which they will additionally receive a tablet device pre-installed with a patient app.

In addition to on time treatment adherence and total treatment adherence, illness and treatment beliefs will be collected via a questionnaire and patient's health status from the EQ5D-5L and SGRQ-C Questionnaire. Key safety assessments are COPD exacerbation and AE/SAE, device deficiencies and device events, drug administration errors, physical exam, vital signs and urine or serum pregnancy test.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: January 22, 2019
• Est. primary completion date: January 22, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent

• Have a total adherence of more than 10% but less than or equal to 70% during Screening period

• Current or ex-smokers who have a smoking history of at least 10 pack years.

• A diagnosed COPD

• Taking Ultibro® Breezhaler® for at least 3 month prior to Visit 1

• Have been in the Screening period = 35 days.

Exclusion Criteria:

• Pregnant or lactating women

• Women of child-bearing potential

• Subjects having a history of reactions/hypersensitivity to inhaled drugs or drugs of a similar class

• Subjects having a history of reactions/hypersensitivity to lactose or any of the other ingredients of trial medication.

• Subjects with relevant concomitant diseases

• Subjects who have had a COPD exacerbation 6 weeks prior to Visit 1 or between V1 and randomization

• Subjects who have had a respiratory tract infection within 3 weeks prior to Visit 1 or between V1 and randomization

• Use of investigational drugs or other investigational devices at the time of enrollment

• Subjects with a preferred inhalation time between 10.00 pm and 2.00 am.

• Subjects taken off Ultibro® Breezhaler® treatment/inhaler use by the investigator during the Screening period for more than 7 days.

• Subjects not returning all Concept2 inhalers received during the Screening period

• Subjects who have demonstrated inability or unwillingness to use the digital system or to fill in questionnaires.

Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Combination Product:
• Concept2 inhaler
Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 µg, capsule added to Concept2 inhaler
• Concept2 inhaler with patient application
Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 µg, capsule added to Concept2 inhaler with application used for monitoring

Locations

Country	Name	City	State
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Hannover
Germany	Novartis Investigative Site	Leipzig
Germany	Novartis Investigative Site	Lubeck
Netherlands	Novartis Investigative Site	Heerlen
Netherlands	Novartis Investigative Site	Helmond
Netherlands	Novartis Investigative Site	Leeuwarden
Netherlands	Novartis Investigative Site	Zutphen

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Germany,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Participant's On-time Adherence Over 24 Weeks of Intervention Compared to Baseline	On-time treatment adherence was defined as percentage of days on which the participant inhaled at least one dose on-time. Dose inhaled on-time was a dose inhaled within (+ or -) 2 hours of the agreed predefined preferred daily inhalation time (PIT). PIT was defined by the participant at study start.	Baseline 6 weeks, intervention 24 weeks
Primary	Change in Participant's Total Adherence Over 24 Weeks of Intervention Compared to Baseline	Total adherence was defined as percentage of days on which the participant inhaled at least one dose and represented the sum of on-time adherence and off-time adherence. Off-time adherence was defined as percentage of days on which the participant did not inhale the daily dose within the (+ or -) 2 hours of the predefined PIT, but outside. The number of doses not inhaled on-time was recorded by the Concept2 inhaler.	Baseline 6 weeks, intervention 24 weeks
Secondary	Change From Participant's 6 Weeks Baseline On-time Adherence to the Participant's On-time Adherence Over the Last Four Weeks of Intervention	On-time treatment adherence was defined as percentage of days on which the participant inhaled at least one dose on-time. Dose inhaled on-time was a dose inhaled within (+ or -) 2 hours of the agreed predefined preferred daily inhalation time (PIT). PIT was defined by the participant at study start.	Baseline, Week 21 - 24
Secondary	Change From Participant's 6 Weeks Baseline Total Adherence to the Participant's Total Adherence Over the Last Four Weeks of Intervention	Total adherence was defined as percentage of days on which the participant inhaled at least one dose and represented the sum of on-time adherence and off-time adherence. Off-time adherence was defined as percentage of days on which the participant did not inhale the daily dose within the (+ or -) 2 hours of the predefined PIT, but outside. The number of doses not inhaled on-time was recorded by the Concept2 inhaler.	Baseline, Week 21 - 24

External Links

•   A Plain Language Trial Summary is available on novartisclinicatrials.com